StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)

Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –

Actinium Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Actinium Pharmaceuticals's profit margin for the twelve months ending Dec 31, 2025 was -37652.2%. For fiscal 2025 it was -37652.2%, against -60269.1% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-37652.2%+22616.9
FY2023Dec 31, 2023-60269.1%−57063.6
FY2022Dec 31, 2022-3205.5%−1040.0
FY2021Dec 31, 2021-2165.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202679.7%+625.4
Q3 FY2025Sep 30, 2025-5701.1%+29125.0
Q3 FY2022Sep 30, 2022-21053.3%−18296.7
Q2 FY2022Jun 30, 2022-17260.0%−15372.4
Q1 FY2022Mar 31, 2022-545.6%+309.7
Q4 FY2021Dec 31, 2021-34826.1%–
Q3 FY2021Sep 30, 2021-2756.7%–
Q2 FY2021Jun 30, 2021-1887.6%–
Q1 FY2021Mar 31, 2021-855.3%–

More Actinium Pharmaceuticals figures

See a number that looks wrong?